| 项目编号 |
PRJCA017237 |
| 项目标题 |
A Pilot Study of Lymphodepletion Intensity for Peripheral Blood Mononuclear Cell-Derived Neoantigen-Specific CD8+ T cell Therapy in Patients with Advanced Solid Tumors |
| 涉及领域 |
cancer |
| 数据类型 |
Exome
Transcriptome or Gene expression
Single cell sequencing
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
Currently, the optimal lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8+ T cell (Neo-T) therapy has yet to be determined. We report a phase 1 study (NCT02959905) of Neo-T therapy with lymphodepletion at various dose intensity in patients with locally advanced or metastatic melanoma and colon cancers that are refractory to standard therapies. The primary end point is safety and the secondary end point is objective response rate (ORR). Results show that the treatment is well tolerated with lymphopenia being the most common adverse event in the highest-intensity lymphodepletion groups. Neo-T infusion-related adverse events are only grade 1-2 in the no lymphodepletion group. The median progression-free survival is 7.1 months (95% CI:3.7-9.8), the median overall survival is 16.8 months (95% CI: 11.9-31.7), and the ORR is 33.3% (3/9) among all groups. Three patients achieve partial response, two of them are in the no lymphodepletion group. One of the partial response patients refractory to prior anti-PD-1 therapy also respond to Neo-T therapy in the group without lymphodepletion pretreatment. Neoantigen specific TCRs are examined in two patients and show delayed expansion after lymphodepletion treatment. In summary, Neo-T therapy without lymphodepletion could be a safe and promising regimen for advanced solid tumors. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2023-06-03 |
| 出版信息 |
| PubMed ID |
文章标题 |
杂志名称 |
Doi |
发表年份 |
| 37301885
|
A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumors
|
Nature Communications
|
10.1038/s41467-023-39225-7
|
2023
|
|
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| No funding support
|
|
|
|
|
|
| 提交者 |
Bo
Li (libo@genomics.cn)
|
| 提交单位 |
BGI-Shenzhen |
| 提交日期 |
2023-05-24 |
